Innate Pharma S.A. (NASDAQ:IPHA) Shares Sold by Optiver Holding B.V.

Optiver Holding B.V. lowered its holdings in Innate Pharma S.A. (NASDAQ:IPHAFree Report) by 63.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,796 shares of the company’s stock after selling 142,301 shares during the period. Optiver Holding B.V. owned approximately 0.10% of Innate Pharma worth $257,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Balyasny Asset Management LLC purchased a new position in shares of Innate Pharma in the third quarter valued at $32,000. Jane Street Group LLC boosted its stake in shares of Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Innate Pharma in the second quarter valued at $133,000. Millennium Management LLC boosted its stake in shares of Innate Pharma by 389.8% in the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock valued at $267,000 after purchasing an additional 57,050 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Innate Pharma by 27.4% in the first quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after purchasing an additional 108,335 shares during the period. Institutional investors and hedge funds own 0.29% of the company’s stock.

Innate Pharma Trading Up 2.4 %

NASDAQ IPHA opened at $2.51 on Tuesday. Innate Pharma S.A. has a 12 month low of $1.81 and a 12 month high of $3.97. The company’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $2.85.

Analysts Set New Price Targets

IPHA has been the subject of several analyst reports. Citigroup decreased their target price on shares of Innate Pharma from $12.00 to $8.00 in a research note on Monday, September 18th. HC Wainwright restated a “buy” rating and issued a $11.50 target price on shares of Innate Pharma in a research note on Wednesday, November 15th.

Get Our Latest Analysis on Innate Pharma

About Innate Pharma

(Free Report)

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s├ęzary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Read More

Want to see what other hedge funds are holding IPHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innate Pharma S.A. (NASDAQ:IPHAFree Report).

Institutional Ownership by Quarter for Innate Pharma (NASDAQ:IPHA)

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.